Expanded Indications in the Adult Cochlear Implant Population

Sponsor
Med-El Corporation (Industry)
Overall Status
Recruiting
CT.gov ID
NCT03236909
Collaborator
(none)
50
6
55.5
8.3
0.2

Study Details

Study Description

Brief Summary

The purpose of this investigation is to expand FDA-approved labeling for MED-EL cochlear implants to include adults who have moderate to profound sensorineural hearing loss and obtain limited benefit from appropriately fit hearing aids.

Condition or Disease Intervention/Treatment Phase
  • Device: MED-EL SYNCHRONY/SYNCHRONY PIN Cochlear Implant System
N/A

Detailed Description

Fifty (50) subjects, 18 years of age and older, will be implanted across the United States and Canada. Subjects with moderate to profound bilateral sensorineural hearing loss will be implanted with the MED-EL SYNCHRONY/SYNCHRONY PIN Cochlear Implant System. .

Limited benefit from amplification is defined by test scores of 60% correct or less in the ear to be implanted (70% or less in the nonimplanted ear) on monosyllabic words in quiet. Subjects will be followed for twelve (12) months post-activation of the SONNETEAS Audio Processor.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Expanded Indications in the Adult Cochlear Implant Population
Actual Study Start Date :
Apr 16, 2018
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Outcome Measures

Primary Outcome Measures

  1. Percent correct words recognition in quiet in implanted ear [Up to twelve (12 months) post-activation]

    CNC (Consonant Nucleus Consonant) word scores will be calculated as percent correct at baseline through 6 months and reported as percentage points improved.

  2. Percent correct of words identified for sentences in noise in implanted ear [Up to twelve (12 months) post-activation]

    AzBio sentence recognition in noise scores will be calculated as percent correct of words in each sentence at baseline through 6 months and reported as percentage points improved.

Secondary Outcome Measures

  1. Patient reported improvement in everyday listening conditions [Up to twelve (12 months) post -activation]

    APHAB (ABBREVIATED PROFILE OF HEARING AID BENEFIT) and SSQ (Spatial and Qualities of Hearing) questionnaires will be used to assess subjective outcomes and reported as improvements from baseline to 6 months post-activation.

  2. Number and proportion of subjects experiencing device related adverse events [Up to twelve (12 months) post-activation]

    Adverse events will be collected and reported throughout the duration of the study.

  3. Residual low frequency hearing [Up to twelve (12) months post-activation]

    HEARRING scale will be used to calculate the percent of hearing preservation for each subject. This data will be summarized through 6 months post-activation.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adults, 18 years of age or older at the time of implantation

  • Moderate to profound hearing loss in the low frequencies and severe to profound hearing loss in the high frequencies, bilaterally as defined by: Low-frequency PTA (250, 500, and 1000 Hz) greater than 40 dB High-frequencies not better than 65 dB (3000 Hz - 8000 Hz)

  • Sensorineural hearing loss, demonstrated by an air-bone gap of less than or equal to 10dB

  • Limited benefit from appropriately fit hearing aids, defined by CNC word score in quiet of 60% or less in the ear to be implanted and 70% or less in the non-implanted ear

  • CNC word score in quiet of greater than or equal to 10% in the ear to be implanted

  • Evidence of appropriately fit hearing aids as determined by the audiologist

  • Bilateral hearing aids should be considered standard of care, except in situations where the audiologist, physician, or potential subject determines that unilateral fit is optimal

  • Hearing aid fit should be verified through accepted measures such as functional gain or real-ear verification

  • If appropriately fit hearing aids have not been worn within the last year, a 30-day hearing aid trial must be completed prior to enrollment in the study

  • Fluent in English

  • No radiological contraindications

  • Ability to undergo general anesthesia

  • Appropriate motivation and expectation levels

  • Stated willingness to comply with all study procedures for the duration of the study

Exclusion Criteria:
  • Evidence that hearing loss is retrocochlear in origin

  • Active middle ear infection

  • Skin or scalp condition precluding use of external audio processor- Suspected cognitive impairment or organic brain dysfunction

  • History of prior use of a hearing implant

Contacts and Locations

Locations

Site City State Country Postal Code
1 Stanford University Stanford California United States 94305
2 University of Miami Miami Florida United States 33136
3 University of North Carolina Chapel Hill North Carolina United States 27599
4 Vanderbilt University Nashville Tennessee United States 37232
5 Medical College of Wisconsin Milwaukee Wisconsin United States 53226
6 Sunnybrook Health Sciences Centre Toronto Ontario Canada M4N 3M5

Sponsors and Collaborators

  • Med-El Corporation

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Med-El Corporation
ClinicalTrials.gov Identifier:
NCT03236909
Other Study ID Numbers:
  • G170111
First Posted:
Aug 2, 2017
Last Update Posted:
Nov 16, 2021
Last Verified:
Nov 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 16, 2021